Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $134.30.

A number of research firms have recently commented on ORKA. Wedbush set a $165.00 price target on Oruka Therapeutics in a research report on Monday, April 27th. BTIG Research reiterated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 14th. Weiss Ratings cut Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, April 30th. Finally, Barclays lifted their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $85.21 on Tuesday. The company’s fifty day moving average is $69.11 and its 200-day moving average is $49.41. The stock has a market cap of $5.14 billion, a price-to-earnings ratio of -43.92 and a beta of -0.35. Oruka Therapeutics has a twelve month low of $12.10 and a twelve month high of $97.78.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, research analysts anticipate that Oruka Therapeutics will post -2.06 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This represents a 0.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total transaction of $550,568.16. Following the completion of the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. The trade was a 19.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 185,407 shares of company stock worth $11,636,307 over the last three months. 23.49% of the stock is currently owned by insiders.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently modified their holdings of ORKA. Avidity Partners Management LP boosted its position in shares of Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after buying an additional 100,000 shares during the period. Glenmede Trust Co. NA raised its position in Oruka Therapeutics by 11.7% in the 1st quarter. Glenmede Trust Co. NA now owns 21,772 shares of the company’s stock valued at $1,068,000 after buying an additional 2,287 shares during the last quarter. Remedium Capital Partners LLC lifted its stake in Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after acquiring an additional 13,247 shares in the last quarter. Royal Bank of Canada lifted its stake in Oruka Therapeutics by 178.5% in the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after acquiring an additional 2,033 shares in the last quarter. Finally, Rock Springs Capital Management LP acquired a new position in Oruka Therapeutics during the 1st quarter worth approximately $202,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.